Humacyte Past Earnings Performance
Past criteria checks 0/6
Humacyte's earnings have been declining at an average annual rate of -19.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 69.4% per year.
Key information
-19.9%
Earnings growth rate
71.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -69.4% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Humacyte: Navigating The FDA Uncertainty And ATEV's Potential
Sep 24Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Aug 16
Humacyte: Pioneering Vascular Solutions With High-Stakes Potential
Jul 17Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation
Jun 05Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High
May 14Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Feb 14Revenue & Expenses Breakdown
How Humacyte makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -153 | 24 | 11 |
| 30 Jun 24 | 0 | -140 | 23 | 7 |
| 31 Mar 24 | 0 | -106 | 20 | 0 |
| 31 Dec 23 | 0 | -111 | 20 | 0 |
| 30 Sep 23 | 0 | -89 | 20 | 55 |
| 30 Jun 23 | 0 | -89 | 20 | 37 |
| 31 Mar 23 | 1 | -29 | 22 | 0 |
| 31 Dec 22 | 2 | -12 | 23 | 0 |
| 30 Sep 22 | 2 | 34 | 23 | 0 |
| 30 Jun 22 | 2 | 28 | 22 | 0 |
| 31 Mar 22 | 1 | -26 | 22 | 0 |
| 31 Dec 21 | 1 | -26 | 21 | 0 |
| 30 Sep 21 | 1 | -85 | 18 | 0 |
| 30 Jun 21 | 2 | -71 | 16 | 0 |
| 31 Mar 21 | 1 | -69 | 14 | 0 |
| 31 Dec 20 | 1 | -67 | 12 | 0 |
| 31 Dec 19 | 6 | -85 | 16 | 0 |
Quality Earnings: HUMA is currently unprofitable.
Growing Profit Margin: HUMA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HUMA is unprofitable, and losses have increased over the past 5 years at a rate of 19.9% per year.
Accelerating Growth: Unable to compare HUMA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HUMA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: HUMA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.